A Comparative Assessment of a New Antacid Formulation Based on Magaldrate

McCafferty, D.F.; Woolfson, A. David

doi:10.1111/j.1365-2710.1983.tb01058.x

Cited by 3 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, the magaldrate efficacy in the treatment of gastroesophageal reflux could be mainly attributed to its ability to rise rapidly and consistently the intragastric pH [22,35]. However, other studies have reported that magaldrate is also able to inactivate pepsin and binding to bile acids and lysolecithin, aggressors in case of gastroesophageal reflux [35,36]. Furthermore, magaldrate activates other gastroprotective mechanisms, such as, increment in gastric mucus secretion [37], stimulation of endogenous prostaglandin E 2 [38] and protection of gastric mucosa of lipid peroxidation [39].…”

Section: Discussionmentioning

confidence: 99%

Fixed Dose Combination of Magaldrate Plus Domperidone Is More Effective than Domperidone Alone in the Treatment of Patients with Gastroesophageal Reflux Symptoms: A Randomized Double-Blind Study

Rodríguez-Sánchez¹,

Rocha-González²,

Valle-Laisequilla³

et al. 2014

View full text Add to dashboard Cite

Gastroeophageal reflux is a condition in which the acidified liquid content of the stomach backs up into the esophagus. The antiacid magaldrate and prokinetic domperidone are two drugs clinically used for the treatment of gastroesophageal reflux symptoms. However, the evidence of a superior effectiveness of this combination in comparison with individual drugs is lacking. A double-blind, randomized and comparative clinical trial study was designed to characterize the efficacy and safety of a fixed dose combination of magaldrate (800 mg)/domperidone (10 mg) against domperidone alone (10 mg), in patients with gastroesophageal reflux symptoms. One hundred patients with gastroesophageal reflux diagnosed by Carlsson scale were randomized to receive a chewable tablet of a fixed dose of magaldrate/domperidone combination or domperidone alone four times each day during a month. Magaldrate/domperidone combination showed a superior efficacy to decrease global esophageal (pyrosis, regurgitation, dysphagia, hiccup, gastroparesis, sialorrhea, globus pharyngeus and nausea) and extraesophageal (chronic cough, hoarseness, asthmatiform syndrome, laryngitis, pharyngitis, halitosis and chest pain) reflux symptoms than domperidone alone. In addition, magaldrate/domperidone combination improved in a statistically manner the quality of life of patients with gastroesophageal reflux respect to monotherapy, and more patients perceived the combination as a better treatment. Both treatments were well tolerated. Data suggest that oral magaldrate/domperidone mixture could be a better option in the treatment of gastroesophageal reflux symptoms than only domperidone.

show abstract

Section: Discussionmentioning

confidence: 99%

Fixed Dose Combination of Magaldrate Plus Domperidone Is More Effective than Domperidone Alone in the Treatment of Patients with Gastroesophageal Reflux Symptoms: A Randomized Double-Blind Study

Rodríguez-Sánchez¹,

Rocha-González²,

Valle-Laisequilla³

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Ант ациды и алгинаты могут применяться как в качестве монотерапии редкой изжоги, не сопровождающейся развитием эзофагита, так и в схемах комплексной терапии ГЭРБ, так как оказываются эффективны в быстром устранении симптомов [124,125] (УУР А, УДД -1).…”

Section: консервативное лечениеunclassified

“…Комбинированный препарат, содержащий магалдрат и симетикон, способен быстро нейтрализовать соляную кислоту и длительно поддерживать стабильный уровень pH, очень активно связывать соли желчных кислот [125]. При его применении наблюдается исчезновение симптомов у большинства пациентов с ГЭРБ [129] (УУР А, УДД -1).…”

Section: консервативное лечениеunclassified

Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease

Ивашкин

Маев

Трухманов

et al. 2020

Rossijskij žurnal gastroènterologii, gepatologii, koloproktolog

View full text Add to dashboard Cite

Ключевые слова: гастроэзофагеальная рефлюксная болезнь, гастроэзофагеальный рефлюкс, неэрозивная рефлюксная болезнь, рефлюкс-эзофагит, пищевод Баррета, манометрия высокого разрешения, pH-импедансометрия Конфликт интересов: авторы заявляют об отсутствии конфликта интересов.

show abstract

Study of antacid effect of the drug Antareit® in healthy volunteers

Zakharov,

Vasilyuk,

Goncharov

et al. 2024

Fk&Fd

View full text Add to dashboard Cite

The aim. Study of pharmacodynamic parameters and confirmation of pharmacodynamic equivalence (bioequivalence) of the drugs Antareit® (INN: magaldrate), chewable tablets, 800 mg (Valenta Pharm JSC, Russia) and Riopan (INN magaldrate), chewable tablets, 800 mg (Takeda GmbH, Germany). Material and methods. An open randomized crossover study was conducted to investigate the pharmacodynamics of the study drug Antareit® and the reference drug Riopan, assessing their bioequivalence after taking 2 chewable tablets of the study or reference drug 3 times a day. The study involved 40 healthy volunteers who were randomized into 2 groups of 20 people depending on the sequence of drug administration in study periods I and II. Intragastric acidity was measured with a pH-probe within 30 minutes before and for one hour after taking the study drugs. Based on the data obtained, 90% confidence intervals (CI) were calculated for the pharmacodynamic parameter AUCABL, reflecting the area above the baseline pH. The safety of the study drugs was assessed by the frequency and severity of adverse events (AEs). Results. Statistical analysis showed that the 90% CI for the ratio of the mean values of the AUC ABL parameter of the study drug to the reference drug did not fall below 80% (90% CI: 80.55–119.49). During the study, 18 adverse events (AEs) were reported in 15.4% (6 of 39) of volunteers in the safety population, and there were no statistically significant differences in the incidence of AEs between groups, nor in the incidence of AEs depending on the drug taken. Conclusion. The studied drugs are pharmacodynamically equivalent and have a similar safety profile when administered repeatedly.

show abstract

A Comparative Assessment of a New Antacid Formulation Based on Magaldrate

Cited by 3 publications

References 14 publications

Fixed Dose Combination of Magaldrate Plus Domperidone Is More Effective than Domperidone Alone in the Treatment of Patients with Gastroesophageal Reflux Symptoms: A Randomized Double-Blind Study

Fixed Dose Combination of Magaldrate Plus Domperidone Is More Effective than Domperidone Alone in the Treatment of Patients with Gastroesophageal Reflux Symptoms: A Randomized Double-Blind Study

Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease

Study of antacid effect of the drug Antareit® in healthy volunteers

Contact Info

Product

Resources

About